Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by josameyeron Feb 19, 2011 9:25am

472 Views

Post# 18163365

Drilling results at Black and Grey Fox?

It has been well over a month since the last drilling results, were made public .The price of Brigus has drifted downward.I think that we are due some drilling results. Also the Calais loan ,I believe to be worth about 11 million dollars owed to Brigus, has not been mentioned by Brigus lately, as I can recall.The loan extention was mentioned by Calais . What are the loan extention detais.A little more news put out by Brigus would be helpful in my opinion.Cheers Josa.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features